[go: up one dir, main page]

WO2005058232A3 - Methods and compositions for the treatment of prolactin-receptor related disorders - Google Patents

Methods and compositions for the treatment of prolactin-receptor related disorders Download PDF

Info

Publication number
WO2005058232A3
WO2005058232A3 PCT/US2004/041308 US2004041308W WO2005058232A3 WO 2005058232 A3 WO2005058232 A3 WO 2005058232A3 US 2004041308 W US2004041308 W US 2004041308W WO 2005058232 A3 WO2005058232 A3 WO 2005058232A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
prolactin
treatment
prolactin receptor
Prior art date
Application number
PCT/US2004/041308
Other languages
French (fr)
Other versions
WO2005058232A2 (en
Inventor
Ross G Clark
Original Assignee
Tercica Inc
Ross G Clark
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tercica Inc, Ross G Clark filed Critical Tercica Inc
Priority to US10/582,047 priority Critical patent/US20080038369A1/en
Publication of WO2005058232A2 publication Critical patent/WO2005058232A2/en
Publication of WO2005058232A3 publication Critical patent/WO2005058232A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides methods and compositions for the treatment, diagnosis, prevention, or amelioration of one or more symptoms of a prolactin receptor-related condition, including, for example, a cancer such as breast cancer or prostate cancer, by administering a growth hormone-based prolactin receptor antagonist and zinc, or administering a growth hormone-based prolactin receptor antagonist to a tissue with an effective local concentration of zinc. The invention further provides pharmaceutical compositions of growth hormone-based prolactin receptor antagonists and zinc useful in the methods of the invention.
PCT/US2004/041308 2003-12-11 2004-12-10 Methods and compositions for the treatment of prolactin-receptor related disorders WO2005058232A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/582,047 US20080038369A1 (en) 2003-12-11 2004-12-10 Methods And Compositions For The Treatment Of Prolactin-Receptor Related Disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US52925203P 2003-12-11 2003-12-11
US52923503P 2003-12-11 2003-12-11
US60/529,235 2003-12-11
US60/529,252 2003-12-11

Publications (2)

Publication Number Publication Date
WO2005058232A2 WO2005058232A2 (en) 2005-06-30
WO2005058232A3 true WO2005058232A3 (en) 2006-01-05

Family

ID=34704270

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/041308 WO2005058232A2 (en) 2003-12-11 2004-12-10 Methods and compositions for the treatment of prolactin-receptor related disorders

Country Status (2)

Country Link
US (1) US20080038369A1 (en)
WO (1) WO2005058232A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754031B2 (en) * 2004-03-08 2014-06-17 Oncolix, Inc. Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
EP2129793A1 (en) 2007-03-20 2009-12-09 Institut National De La Sante Et De La Recherche Medicale Constitutively active mutants of the prolactin receptor
SG192527A1 (en) 2008-07-31 2013-08-30 Sigma Tau Ind Farmaceuti Composition useful for the prevention or reduction of the progression of prostate cancer
EP2531211A4 (en) * 2010-02-03 2013-10-23 Orbis Health Solutions Llc Method for sensitizing cells to cancer therapy
US20130244936A1 (en) * 2010-06-04 2013-09-19 Vincent Goffin Constitutively active prolactin receptor variants as prognostic markers and therapeutic targets to prevent progression of hormone-dependent cancers towards hormone-independence
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
TWI641620B (en) 2013-08-21 2018-11-21 再生元醫藥公司 Anti-prlr antibodies and uses thereof
WO2016197059A1 (en) * 2015-06-04 2016-12-08 Vijaykumar Rajasekhar Compositions and methods for the treatment of sexual dysfunction
AU2017366873A1 (en) 2016-11-29 2019-06-13 Regeneron Pharmaceuticals, Inc. Methods of treating PRLR positive breast cancer
WO2019169330A1 (en) * 2018-03-02 2019-09-06 Oncolix, Inc. Method for treating cancers expressing prolactin receptor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677171A (en) * 1988-01-12 1997-10-14 Genentech, Inc. Monoclonal antibodies directed to the HER2 receptor
US5854026A (en) * 1988-10-28 1998-12-29 Genentech, Inc. Human growth hormone variant having enhanced affinity for human growth hormone receptor at site 1

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429186B1 (en) * 1991-05-10 2002-08-06 Genentech, Inc. Ligand antagonists for treatment of breast cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677171A (en) * 1988-01-12 1997-10-14 Genentech, Inc. Monoclonal antibodies directed to the HER2 receptor
US5854026A (en) * 1988-10-28 1998-12-29 Genentech, Inc. Human growth hormone variant having enhanced affinity for human growth hormone receptor at site 1

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHEN ET AL: "In vivo studies of the anti-tumor effects of a human prolactin antagonists,hPRL-G129R", INTERNATIONAL J ONCOLOGY, vol. 20, 2002, pages 813 - 818, XP002993163 *
CUNNINGHAM ET AL: "Zinc Mediation of the Binding of Human Growth Hormone to the Human Prolactin Receptor", SCIENCE, vol. 250, 21 December 1970 (1970-12-21), pages 1709 - 1712, XP008056741 *
FUH ET AL: "Prolactin Receptor Antagonists That Inhibit the Growth of Breast Cancer Cell Lines", J. BIOLOCIGAL CHEMISTRY, vol. 270, no. 22, 2 June 1995 (1995-06-02), pages 13133 - 13137, XP002993162 *
MAH ET AL: "Hyperprolactinemia: Etiology, Diagnosis, and Management", SEMIN REPROD MED., vol. 20, no. 4, 2002, pages 365 - 374, XP008016098 *
ROSOFF ET AL: "Effect of Perphenazine on Growth and Zinc-65 Uptake of the Rat Prostatic Adenocarcinoma, R 3327", THE PROSTATE, vol. 3, 1982, pages 615 - 622, XP008056680 *
XU ET AL: "A Molecular Mimic of Phosphorylated Prolactin Markedly Reduced Tumor Incidence and Size When DU145 Human Prostate Cancer Cells Were Grown in Nude Mice", CANCER RESEARCH, vol. 61, 15 August 2001 (2001-08-15), pages 6098 - 6104, XP002993164 *

Also Published As

Publication number Publication date
US20080038369A1 (en) 2008-02-14
WO2005058232A2 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
WO2007048026A3 (en) Cgrp peptide antagonists and conjugates
WO2005107726A3 (en) Method for the treatment of back pain
IL179599A0 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2006052723A3 (en) G protein coupled receptor agonists and antagonists and methods of use
WO2005107747A3 (en) Diindolymethane formulations for the treatment of leiomyomas
TW200604168A (en) Azaindoles useful as inhibitors of rock and other protein kinases
WO2005037259A3 (en) Methods and compositions for the prevention or treatment of neoplasia comprising a cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
WO2003014309A3 (en) Interleukin-1 receptors in the treatment of diseases
WO2003057837A8 (en) Methods for using anti-muc18 antibodies
WO2005105780A3 (en) Compositions useful as inhibitors of rock and other protein kinases
SG161261A1 (en) Lactam compounds and their use as pharmaceuticals
WO2007067341A3 (en) Compositions and methods for increasing insulin sensitivity
WO2006034154A3 (en) Salts of 5-azacytidine
WO2008128126A8 (en) Compositions and methods for prophylaxis and treatment of addictions
WO2006071274A3 (en) Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer’s disease
WO2007016352A3 (en) Oral liquid losartan compositions
WO2005009387A3 (en) Azepine derivatives as pharmaceutical agents
WO2005019247A3 (en) Cyclic peptide and imaging compound compositions and uses for targeted imaging and therapy
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
TW200510367A (en) Novel lapachone compounds, their preparation, and the use thereof
WO2005058232A3 (en) Methods and compositions for the treatment of prolactin-receptor related disorders
TW200633978A (en) 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists
WO2005011590A3 (en) Compositions and methods for restoring sensitivity to treatment with her2 antagonists
WO2006060753A3 (en) Diagnosis and treatment of alzheimer's disease
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase
WWE Wipo information: entry into national phase

Ref document number: 10582047

Country of ref document: US